Table 2.
Ongoing clinical trials testing immunotherapy combined with chemotherapy in breast cancer.
| Immunotherapy | Treatment | Additional Treatments | Settings | Clinical Trial Phase | Status | Clinical Trial Reference |
|---|---|---|---|---|---|---|
| Vaccines | Talimogene laherparepvec | Paclitaxel | TNBC | I/II | Active, not recruiting | NCT02779855 |
| Mammaglobin-A DNA | Neoadjuvant hormonal therapy | HR+ BC | IB | Recruiting | NCT02204098 | |
| PVX-410 | Alone/Combined with Durvalumab | Stage II/ III TNBC | IB | Active, not recruiting | NCT02826434 | |
| Nelipepimut-S + GM-CSF | Trastuzumab | HER2+ BC high risk | II | Completed * | NCT02297698 | |
| Monoclonal antibodies/antibody drug conjugates | QL1209 | Trastuzumab, docetaxel | Early/locally advanced ER/PR- BC | III | Not yet recruiting | NCT04629846 |
| Pyrotinib | Epirrubicin, cyclophosphamide͢͢͢, taxanes, trastuzumab | Moderate/high risk early BC | II/III | Not yet recruiting | NCT04290793 | |
| Trastuzumab Deruxtecan | Pertuzumab, placebo | Metastatic | III | Recruiting | NCT04784715 | |
| Pyrotinib | Trastuzumab, docetaxel | Metastatic | III | Recruiting | NCT03863223 | |
| Margetuximab | Capecitabine, vinorelbine, Gemcitabine, Eribulin | Metastatic | III | Active, not recruiting | NCT02492711 | |
| Paclitaxel, pertuzumab | Neoadjuvant | II | Recruiting | NCT04425018 | ||
| Anti-PD-1 | Nivolumab | Nanoparticle albumin-bound paclitaxel ± Gemcitabine or Carboplatin | Metastatic | II | Recruiting | NCT02309177 |
| Nivolumab | Paclitaxel, cyclophosphamide, endrocine therapy, anthracycline | Metastatic | III | Active, not recruiting | NCT0419066 | |
| Nivolumab | Low dose doxorubicin, cisplatin | Metastatic | II | Recruiting | NCT04159818 | |
| Pembrolizumab | Carboplatin | Metastatic | II | Recruiting | NCT03213041 | |
| Pembrolizumab | Abemaciclib | Metastatic | Ib | Active, not recruiting | NCT02779751 | |
| Pembrolizumab | Trastuzumab emtansine | Metastatic | Ib | Active, not recruiting | NCT03032107 | |
| Anti-PD-L1 | Atezolizumab | Carboplatin | Metastatic | II | Active, not recruiting | NCT03206203 |
| Durvalumab | Hypofractionated RT, Tremelimumab | Metastatic | I | Active, not recruiting | NCT02639026 | |
| Avelumab | Palbociclib and Fulvestrant | Metastatic | II | Active, not recruiting | NCT03147287 |
* This clinical trial is already completed but final results have not been published yet. BC: Breast cancer; ER/PR-: Estrogen and progesterone receptor-negative; GM-CSF: Granulocyte-macrophage-colony stimulating factor; HER2+: Human epidermal growth factor receptor 2positive; HR+: Hormone receptor-positive; PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand 1; PVX: Peptide vaccine; RT: radiotherapy; TNBC: Triple negative breast cancer.